Abstract
ABSTRACT
Background
Routine collection of patient perspectives about psoriasis and its treatment through patient reported outcome measurements (PROMs), alongside clinician reported outcome measurements (CROMs), may improve clinical outcomes and facilitate shared decision making.
Objectives
This study aimed to assess the impact of using PROMs on evaluating treatments in patients with moderate to severe psoriasis.
Methods
The SUMMER Project is a multicenter study examining the characteristics, severity, treatment, healthcare resource use and quality‐of‐life impact of moderate to severe psoriasis patients in Spain. Data extracted from medical records, partly through natural language processing, included demographics, clinical data and CROMs (Psoriasis Area Severity Index‐PASI and body surface area‐BSA). PROMs collected through a platform every 3 months included Dermatology life quality index (DLQI) to assess HRQoL, 10‐point Visual Analogic Scale (VAS) to assess psoriasis global impact, and Treatment Satisfaction Questionnaire for Medication (TSQM‐9).
Results
Out of 222 patients from 5 hospitals, 147 were analyzed. The mean age was 48.2 years, with 58.5% males. Most (88.9%) were on biologic treatment for psoriasis, while 18.8% were on conventional systemic treatment. At the start, 7.3% had severe psoriasis symptoms (PASI ≥ 5 and/or BSA ≥ 3). The median baseline DLQI was 3.0, with 21.0% scoring ≥ 5. The average VAS score was 2.4, with 12.5% scoring ≥ 7. Mean global TSQM‐9 score was 80.6. During follow‐up, 9.6% changed treatment. At the time of change, 53.8% had mild symptoms (PASI ≤ 3), 30.8% had severe symptoms (PASI ≥ 5), and 68.8% had high DLQI and/or VAS scores. Those who changed treatment showed significant improvement in DQLI and VAS scores.
Conclusions
Most psoriasis patients maintained stable treatment, with good HRQoL. Few patients reported a significant impact on HRQoL and changed their treatment. PROs can play an important role in shared decision making to change treatment in routine clinical practice, even for patients achieving excellent clinical outcomes.